Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer
β Scribed by Barbara G. Campling; Inder R. Sarda; Kathy A. Baer; Stephen C. Pang; Heather M. Baker; Wycliffe S. Lofters; T. Geoffrey Flynn
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 941 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Tumors and tumor cell lines from two patients with small cell lung carcinoma (sclc) (one with and one without hyponatremia) were studied. ectopic production and prohormone processing of atrial natriuretic peptide (anp) were investigated to determine if a biologically active peptide w
## Abstract Atrial natriuretic peptide (ANP) is a 28βamino acid polypeptide that is primarily secreted by the heart. ANP is believed to be a hormone that regulates cardiovascular dynamics and renal functions; however, studies conducted in the past few decades revealed that ANP is also a potent lipo
Atrial natriuretic peptide (ANP) is a fluid-regulating peptide hormone that promotes vasorelaxation, natriuresis, and diuresis. The mechanisms for the release of ANP and for its clearance from the circulation play important roles in modulating its biological effects. Recently, we have reported that
From 1976 to 1980,18 of the 250 patients (7%) seen with small cell carcinoma of the lung had clinically evident inappropriate secretion of antidiuretic hormone (ADH). Hyponatremia was usually severe (1 16 f 7 meq/l), and eight patients showed symptoms of water intoxication at the time of diagnosis.